

## TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 16 July 2021

In compliance with the information duties set out in article 226 of the Consolidated Text of the Securities Market Act, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the National Securities Market Commission the following

### PRIVILEGED INFORMATION

The Board of Directors of ROVI, at its meeting held today, has unanimously and acting on a report from the Appointments and Remunerations Committee, agreed to appoint the current Chief Executive Officer, Mr. Juan López-Belmonte Encina, as new Chairman of the Board of Directors of ROVI.

The Board of Directors has expressed the profound gratitude and respect of the Company and all of its employees towards the former Chairman, Mr. Juan López-Belmonte López.

The Appointments and Remunerations Committee has considered that according to the career of Mr. Juan López-Belmonte Encina it is clear that he has unquestionable knowledge to perform the functions as Chairman of the Board, as well as a deep and extensive expertise in the Company, the Rovi Group and the sector in which it develops its activity, making him the suitable candidate to occupy such position.

Mr. Juan López-Belmonte Encina will continue to act also as a Chief Executive Officer (*Consejero Delegado*).

It is hereby stated that the Company has already appointed a lead independent director (consejero coordinador), Mr. Marcos Peña Pinto, among its independent directors.

Mr. Juan López-Belmonte Encina  
Chairman of the Board of Directors and Chief Executive Officer.  
Laboratorios Farmacéuticos ROVI, S.A